<SEC-DOCUMENT>0001193125-22-111718.txt : 20220526
<SEC-HEADER>0001193125-22-111718.hdr.sgml : 20220526
<ACCEPTANCE-DATETIME>20220420210753
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-22-111718
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220420

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g390834g0405034627553.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 5, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States
Securities and Exchange Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Life Sciences </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, N.E. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention:
&nbsp;&nbsp;&nbsp;&nbsp;Christine Torney </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vanessa Robertson </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Kazia Therapeutics Ltd </B></P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the fiscal year ended June&nbsp;30, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Filed October&nbsp;7, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>File <FONT STYLE="white-space:nowrap">No.&nbsp;000-29962</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Ltd (the
&#147;<B>Company</B>&#148;) is providing this letter in response to comments (the &#147;<B>Comments</B>&#148;) received from the staff of the U.S. Securities and Exchange Commission&#146;s Division of Corporation Finance (the
&#147;<B>Staff</B>&#148;) by letter dated March&nbsp;22, 2022, with respect to the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> that was filed on October&nbsp;7, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set forth below is the Company&#146;s response to the Comments, which for your convenience we have incorporated into this response letter. Capitalized terms
used in this response letter but not otherwise defined in this response letter shall have the meanings set forth in the Annual Report. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Form <FONT
STYLE="white-space:nowrap">20-F</FONT> for the fiscal year ended June&nbsp;30, 2021</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Item 5. Operating and Financial Review and Prospects</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>A. Operating Results</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Expenses, page 22</U> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please provide us with proposed disclosure to be included in future periodic reports which separately
quantifies your research and development expense by project. If you do not track your research and development costs by project, disclose that fact as well as why you do not maintain and evaluate research and development costs by project.
</I></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">We acknowledge your comment and propose to disclose research and development expense by project in our future
periodic reports in the following format (disclosures shown for FY21 report for illustrative purposes): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>A$&#146;000</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>FY21</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>FY20</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paxalisib</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Phase II trial</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- GBM Agile trial</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- other paxalisib</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EVT801</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cantrixil</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D salaries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortisation of licensed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total R&amp;D expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Item 18. Financial Statements</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note 5. Revenue, page <FONT STYLE="white-space:nowrap">F-20</FONT></U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Please tell us your consideration of providing disclosure of the
<FONT STYLE="white-space:nowrap">out-license</FONT> agreements with Oasmia and Simcere to separately quantify upfront payments and milestone payments by type, as these both appear to be material agreements. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">We offer the following comments in relation to this question: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is the Company&#146;s view that we have complied with the disclosure requirements of IFRS 15 in our annual
report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We note that disclosure of the revenue earned from our <FONT STYLE="white-space:nowrap">out-license</FONT>
agreements with&nbsp;Oasmia and Simcere appears on pages 40 &#150; 41 of our annual report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> showing that all revenue received in fiscal 2021 represents up front payments. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In future periodic reports, we will give consideration to providing additional voluntary disclosure in Note 5 to
the financial statements, separately identifying upfront payments and milestone payments by type. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We appreciate your consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please feel free to
contact me via email <U>gabrielle.heaton@kaziatherapeutics.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours sincerely, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>/s/ Gabrielle
Heaton&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gabrielle Heaton </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director,
Finance&nbsp;&amp; Administration </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g390834g0405034627553.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g390834g0405034627553.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !K QL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **"<#)K*L_$.G
MW]Z;2&1_,YVEEP'QZ&J4)23:6Q$JD(M*3M<U:*XZT\1:G+XC%JZKY32F,P[.
M5'KGKQUHU?Q#J=IKS6T(41HRA8BF3)G'?KS[5O\ 5*G-RZ;7.3Z_2Y.?6U['
M8T5EZAX@L=-N$@N&?S& )"KG:/>M-&5T5U(*L,@CN*P<)))M;G7&I"3<8O5"
MT445)84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YWQ!K&FPS+97EHUS
MC#MC^#_Z]=%7/>(K'1_,CO-1>2-C\F(SS)CMBML/R\_O7^1S8OG]D^2WSV+M
MYJ-AHVA"[*8M%0;$C7[V>@ ]\UC^#[30I_.U/2[>6*;<8V25L^7GG ]CQ6U)
M!INM:)Y1"R6+I@8)&W'Z@C%8GA+5]"\Z32=*AGBZR!Y>?-QP3G/T_"N2I=55
MS?CO<];#6>#E[.]]+V^&Q9\2Z_/ILL=K:!1*R[V=AG [ "HO#GB*YOKLV=YM
M9V4LDBKCIU!JWX@\/'5GCG@D6.=%VD/T8?XU'H'AMM,N#=7,B/-MVHJ=%SU.
M?6O23H>PM]K\;GSSCBOK5U\/X6(O&%GH@M8]1U6"61HR(T$38+YYVGVZUI:1
MJ5CK6C":"+;; &-XI%^[@<CZ8K+\7ZSI%LD>FZG;37 E D(CX* ' ;.>O6M:
MPATS2-$4VP$=B$\W<23D'G)[DFO-AK5?+_P3Z*MI@X^TO>[M?X;=3-T/6=+:
M^:QLK(VZR$E7X^?'KW'%=+7.:#;:'->27>G^894_@DS\F>X%='79B.7G]U/Y
MGCX/G]E[S3[6V/)?C?\ ZG0_]^;^25R#^#VO/AS:>([&,M-"TJWD8YW('.'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
